Nilotinib Stada (Nilotinib)

Nilotinib works by binding to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, locking the enzyme in an inactive state. This blocks downstream signaling pathways that promote leukemic cell growth and survival, leading to reduced proliferation and increased apoptosis of malignant cells.

The dose of Nilotinib Stada is individualized by the prescribing physician based on the patient’s disease phase, prior therapy, liver function, and potential drug interactions. No fixed regimen can be stated here; the prescriber sets the appropriate strength and schedule for each patient.

Safety data for Nilotinib in pregnancy and lactation are limited. The drug is generally not recommended for use during pregnancy or while breastfeeding because potential risks to the fetus or infant cannot be excluded. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nilotinib Stada. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

The primary alternative to Nilotinib is imatinib, the first‑generation BCR‑ABL inhibitor. Nilotinib is a second‑generation agent with higher potency and a broader activity against certain imatinib‑resistant mutations. It often achieves faster and deeper molecular responses, but it also carries a distinct safety profile, including a higher risk of QT prolongation.

Nilotinib Stada should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place and avoid exposure to excessive heat or humidity. Do not store in the bathroom or near a kitchen sink.

Nilotinib is taken orally, usually as whole tablets swallowed with a moderate‑fat meal to improve absorption. It should be taken at the same times each day, and patients should avoid grapefruit juice or other strong CYP3A4 modulators unless directed by a healthcare professional.

The most serious adverse events include QT interval prolongation, which can lead to life‑threatening arrhythmias; severe hepatotoxicity manifested by elevated liver enzymes or jaundice; pancreatitis; and profound neutropenia that raises infection risk. Patients should be monitored regularly for cardiac, hepatic and hematologic parameters.

Nilotinib should not be used by individuals with known hypersensitivity to the drug or its excipients, patients with a history of prolonged QT interval, or those with severe hepatic impairment. Caution is also advised for patients with uncontrolled cardiovascular disease, active infections, or concurrent use of strong CYP3A4 inhibitors.